Navigation Links
Medicago Receives Regulatory Approval and Commences Phase II Clinical Testing of its Avian Influenza Vaccine
Date:11/1/2010

will receive an injection of either a placebo or the H5N1 vaccine at varying doses to determine the optimal dose. In the second part of the study, healthy adults will receive an injection of either a placebo or the H5N1 vaccine at the optimal dose. Interim-results of this study are expected in less than three months.

"The initiation of our Phase II clinical trial is an important step in the development of our plant-based VLP vaccines, which we believe are highly effective, cross-protective, less expensive and faster to produce than current influenza vaccines. It also demonstrates our ability to advance candidates through clinical development," said Andy Sheldon, President and CEO of Medicago. "Our platform is very versatile and to date, we have been able to produce a broad array of other proteins with potential use in the life science industry. This clinical trial therefore provides additional validation for our rapid and cost-effective technology platform offering." About Medicago Medicago is committed to provide highly effective and affordable vaccines based on proprietary Virus-Like Particle (VLP) and manufacturing technologies. Medicago is developing VLP vaccines to protect against H5N1 pandemic influenza, using a transient expression system which produces recombinant vaccine antigens in non-transgenic plants. This technology has potential to offer advantages of speed and cost over competitive technologies. It could deliver a vaccine for testing in about a month after the identification and reception of genetic sequences from a pandemic strain. This production time frame has the potential to allow vaccination of the population before the first wave of a pandemic strikes and to supply large volumes of vaccine antigens to the world market. Additional information about Medicago is available at www.medicago.com.

Forward Looking Statements

This news release includes certain forward-loo
'/>"/>

SOURCE Medicago Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Medicago initiates work on Swine Flu strain
2. Medicago succesfully expresses VLP antigen for A H1N1 strain
3. Medicagos H1N1 pandemic vaccine candidate shows positive response in 100% of vaccinated animals after a single dose
4. Medicago receives regulatory approval to begin human clinical testing with its avian flu pandemic vaccine
5. Medicago begins human clinical testing with its avian flu pandemic vaccine
6. Medicago awarded contract by the U.S. Army to explore applications of its plant-based technology in renewable energy
7. Medicago to present at the U.S. Department of Health and Human Services Global Health Security Initiative Workshop
8. Medicago reports positive Phase I results for its avian flu pandemic vaccine
9. Medicago named in Presidential report on meeting the challenges of pandemic influenza
10. Medicago discovers breakthrough method of preparing plant derived recombinant proteins and VLPs and files two PCT patent applications
11. Medicago holds official groundbreaking ceremony for its U.S. commercial grade vaccine facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Bryan-College Station, Texas (PRWEB) September 18, 2014 ... University System Chancellor John Sharp, Texas A&M Health ... from the U.S. Department of Health and Human ... GSK today dedicated a national pandemic influenza vaccine ... will serve as an anchor for the Texas ...
(Date:9/18/2014)... , Sept. 18, 2014 Research ... "Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, ... report to their offering. The global ... CAGR of 22.7% from 2014 to 2019. Factors such ... growing adoption of companion diagnostics by the pharmaceutical industry, ...
(Date:9/18/2014)... 18, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ... concurrent but separate underwritten offerings of 10,000,000 shares of ... of $2.00 per share, for expected gross proceeds of ... Convertible Preferred Stock at a price to the public ... $20 million. Each share of Series A Convertible Preferred ...
(Date:9/18/2014)... diseases that afflict skeletal growth through abnormalities in ... fetal stage and is caused by genetic mutations. ... factor receptor 3 (FGFR3) has been associated with ... a skeletal dysplasia that cause serious respiratory problems ... (ACH), which causes stunted growth and other complications ...
Breaking Biology Technology:Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 3Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 4Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 3Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3Researchers use iPS cells to show statin effects on diseased bone 2Researchers use iPS cells to show statin effects on diseased bone 3
... Arpida Ltd,(SIX: ARPN) announced today its financial results for the six ... to date, - Regulatory setback for intravenous iclaprim in ... - Company restructuring completed, , Cash ... CFO Harry Welten, MBA, commented: "Our cost-saving measures ...
... , , , , ... the healthcar e field using technology in ... patient care, what isn,t clear is the exact role technology will play ... the right information, be it clinical or administrative, at the right time, ...
... particles have been used to bring stem cells to ... to increase the capacity of cells to repair damaged ... disciplinary research, published in The Journal of the ... technique where endothelial progenitor cells a type of ...
Cached Biology Technology:Arpida Reports Interim Results For Six Months to 30 June 2009 2Healthcare Continues to Use OnBase in 'Meaningful' Ways 2Healthcare Continues to Use OnBase in 'Meaningful' Ways 3Healthcare Continues to Use OnBase in 'Meaningful' Ways 4Nanomagnets guide stem cells to damaged tissue 2
(Date:9/18/2014)... that prompts millions of Americans to undertake jaunts into the ... a little longer within a century, according to new research. ... areas of the United States as summer temperatures linger later ... Global Ecology and Biogeography . For instance, the paper ... tree of New Hampshire could change color one to ...
(Date:9/18/2014)... genetic information is stored in DNA, tiny strands of ... our bodies. To express this genetic data, our DNA ... instructions into proteins that perform tasks in our cells. ... type of RNA molecule. Unlike all other known RNAs, ... Although circRNA molecules are abundant, little has been known ...
(Date:9/18/2014)... AZ, Sept. 18, 2014 -- Arizona turned its newborn ... just a few short months, earning it the first-ever Newborn ... The March of Dimes presented Will Humble, M.P.H., Arizona,s Department ... held here today. Mr. Humble established a policy of full ... to send newborn blood samples to the lab for analysis, ...
Breaking Biology News(10 mins):Fall foliage season may be later, but longer on warmer Earth 2Fall foliage season may be later, but longer on warmer Earth 3Fall foliage season may be later, but longer on warmer Earth 4Scientists find how mysterious 'circular RNA' is formed, claim muscular dystrophy link 2March of Dimes honors Arizona with first-ever newborn screening award 2March of Dimes honors Arizona with first-ever newborn screening award 3
... rise, so does the pressure on the plant kingdom. The ... will absorb some of the extra CO 2 and ... now, researchers have hypothesized about one major roadblock: nitrogen. ... they take up from the atmosphere. The more they get, ...
... Wash.There really is a balance of nature, but as accepted ... Washington State University researchers writing in the journal Nature ... typical of organic farms work better at fighting pests and ... pests and their natural enemies in potatoes and found organic ...
... Alberta, June 30, 2010 Innovotech Inc. (TSX-V: IOT), ... has secured funding in excess of $900,000 from Agriculture ... its unique, environmentally friendly seed treatment and plant spray ... infections. "With the potential to increase crop yields ...
Cached Biology News:Nitrogen pollution alters global change scenarios from the ground up 2Nitrogen pollution alters global change scenarios from the ground up 3'Balanced' ecosystems seen in organic ag better at controlling pests 2
...
prototype Nco I...
Based on Silica membrane matrix beads. The kit is designed for the purification of DNA (20 bp - 100 bp) from TAE/TBE agarose gels. Run time is approximately 45 minutes....
Modified and insect cell culture tested....
Biology Products: